Computational Methodology for Peptide Vaccine Design for Zika Virus: A Bioinformatics Approach

  • Ashesh Nandy
  • Smarajit Manna
  • Subhash C. Basak
Part of the Methods in Molecular Biology book series (MIMB, volume 2131)


With the increasing frequency of viral epidemics, vaccines to augment the human immune response system have been the medium of choice to combat viral infections. The tragic consequences of the Zika virus pandemic in South and Central America a few years ago brought the issues into sharper focus. While traditional vaccine development is time-consuming and expensive, recent advances in information technology, immunoinformatics, genetics, bioinformatics, and related sciences have opened the doors to new paradigms in vaccine design and applications.

Peptide vaccines are one group of the new approaches to vaccine formulation. In this chapter, we discuss the various issues involved in the design of peptide vaccines and their advantages and shortcomings, with special reference to the Zika virus for which no drugs or vaccines are as yet available. In the process, we outline our work in this field giving a detailed step-by-step description of the protocol we follow for such vaccine design so that interested researchers can easily follow them and do their own designing. Several flowcharts and figures are included to provide a background of the software to be used and results to be anticipated.

Key words

Peptide vaccine Sequence descriptors Vaccine design protocol Alignment-free techniques Average solvent accessibility (ASA) and protein variability Epitopes Graphical methods 



We would like to acknowledge with thanks the help provided by Mr. Tathagata Dutta in software and graph rendering.


  1. 1.
    Nandy A, Basak SC (2017) The epidemic that shook the world—the Zika virus rampage. Explor Res Hypothesis Med 2(3):43–56. Scholar
  2. 2.
    Riedel S (2005) Edward Jenner and the history of smallpox and vaccination. Proc (Baylor Univ Med Cent) 18(1):21–25CrossRefGoogle Scholar
  3. 3.
    Fu ZF (1997) Rabies and rabies research: past, present and future. Vaccine 15:S20–S24CrossRefGoogle Scholar
  4. 4.
    Roy P, Nandy A, Basak SC (2019) Zika virus—the quest for vaccines. In: Basak SC, Bhattacharjee AK, Nandy A (eds) Zika virus surveillance, vaccinology and anti-Zika drug discovery: computer-assisted strategies to combat the menace. Nova Science Publishers Inc., New YorkGoogle Scholar
  5. 5.
    Chit A, Parker J, Halperin SA, Papadimitropoulos M, Krahn M, Grootendorst P (2014) Toward more specific and transparent research and development costs: the case of seasonal influenza vaccines. Vaccine 32(26):3336–3340. Scholar
  6. 6.
    Backert L, Kohlbacher O (2015) Immunoinformatics and epitope prediction in the age of genomic medicine. Genome Med 7:119CrossRefGoogle Scholar
  7. 7.
    Tomar N, De RK (2014) Immunoinformatics: a brief review. In: De RK TN (ed) Methods Mol Biol, vol 1184. Springer Science+Business Media, New York. Scholar
  8. 8.
    Poland GA, Kennedy RB, Ovsyannikova IG (2011) Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog 7:e1002344CrossRefGoogle Scholar
  9. 9.
    Poland GA, Whitaker JA, Poland CM, Ovsyannikova IG, Kennedy RB (2016) Vaccinology in the third millennium: scientific and social challenges. Curr Opin Virol 17:116–125CrossRefGoogle Scholar
  10. 10.
    Rappuoli R (2001) Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19:2688–2691CrossRefGoogle Scholar
  11. 11.
    Purcell AW, McCluskey J, Rossjohn J (2007) More than one reason to rethink the use of peptides in vaccine design. Nat Rev 6:404–414Google Scholar
  12. 12.
    Ghosh A, Nandy A, Nandy P (2010) Computational analysis and determination of a highly conserved surface exposed segment in H5N1 avian flu and H1N1 swine flu neuraminidase. BMC Struct Biol 10:6. Scholar
  13. 13.
    Sarkar T, Das S, De A, Nandy P, Chattopadhyay S, Chawla-Sarkar M, Nandy A (2015) H7N9 influenza outbreak in China 2013: in silico analyses of conserved segments of the hemagglutinin as a basis for the selection of peptide vaccine targets. Comput Biol Chem 59:8–15CrossRefGoogle Scholar
  14. 14.
    Ghosh A, Chattopadhyay S, Chawla-Sarkar M et al (2012) In Silico study of rotavirus VP7 surface accessible conserved regions for antiviral drug/vaccine design. PLoS One 7:e40749. Scholar
  15. 15.
    Dey S, De A, Nandy A (2016) Rational design of peptide vaccines against multiple types of human papillomavirus. Cancer Inform 15:1–16. Scholar
  16. 16.
    Dey S, Nandy A, Basak SC, Nandy P, Das S (2017) A bioinformatics approach to designing a Zika virus vaccine. Comput Biol Chem 68:143–152. Scholar
  17. 17.
    Shawan MMAK, Mahmud HA, Hasan MM et al (2014) In Silico Modeling and Immunoinformatics probing disclose the epitope based peptide vaccine against Zika virus envelope glycoprotein. Ind J Pharma Biol Res 2:44–57Google Scholar
  18. 18.
    Badawi MM, Osman MM, Alla AAEF et al (2016) Highly conserved epitopes of ZIKA envelope glycoprotein may act as a novel peptide vaccine with high coverage: Immunoinformatics approach. Am J Biomed Res 4:46–60. Scholar
  19. 19.
    Dar H, Zaheer T, Rehman MT et al (2016) Prediction of promiscuous T-cell epitopes in the Zika virus polyprotein: an in silico approach. Asian Pac J Tropical Med 9:844–850. Scholar
  20. 20.
    Dikhit MR, Ansari MY, Vijaymahantesh K et al (2016) Computational prediction and analysis of potential antigenic CTL epitopes in Zika virus: a first step towards vaccine development. Infect Genet Evol 45:187–197. Scholar
  21. 21.
    Mirza MU, Rafique S, Ali A et al (2016) Towards peptide vaccines against Zika virus: immunoinformatics combined with molecular dynamics simulations to predict antigenic epitopes of Zika viral proteins. Sci Rep 6:37313. Scholar
  22. 22.
    Nandy A, Basak SC (2016) A brief review of computer-assisted approaches to rational design of peptide vaccines. International J Mol Sci 17:666CrossRefGoogle Scholar
  23. 23.
    Dey S, Das S, Nandy A (2017) Characterization of Zika and other human infecting Flavivirus envelope proteins and determination of common conserved epitope regions. EC Microbiol 8:29–46Google Scholar
  24. 24.
    Kuno G, Chang GJ (2007) Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses. Arch Virol 152:687–696. Scholar
  25. 25.
    Sirohi D, Chen Z, Sun L, Klose T, Pierson TC, Rossmann MG et al (2016) The 3.8 Å resolution cryo-EM structure of Zika virus. Science 352(6284):467–470. Scholar
  26. 26.
    Dai L, Song J, Lu X, Deng Y-Q, Musyoki AM, Cheng H et al (2016) Structures of the Zika virus envelope protein and its complex with a Flavivirus broadly protective antibody. Cell Host Microbe 19:696–704. Scholar
  27. 27.
    Nandy A (1994) A new graphical representation and analysis of DNA sequence structure: I. methodology and application to globin genes. Curr Sci 66:309–314Google Scholar
  28. 28.
    Raychaudhury C, Nandy A (1999) Indexing scheme and similarity measures for macromolecular sequences. J Chem Inf Comput Sci 39:243–247CrossRefGoogle Scholar
  29. 29.
    Nandy A, Nandy P (2003) On the uniqueness of quantitative DNA difference descriptors in 2D graphical representation models. Chem Phys Lett 368:102–107CrossRefGoogle Scholar
  30. 30.
    Nandy A, Harle M, Basak SC (2006) Mathematical descriptors of DNA sequences: development and applications. ARKIVOC 9:211–238Google Scholar
  31. 31.
    Nandy A, Ghosh A, Nandy P (2009) Numerical characterization of protein sequences and application to voltage-gated sodium channel alpha subunit phylogeny. In Silico Biol 9:77–87. Scholar
  32. 32.
    National Centre for Biotechnology Information—BLAST (2019) Accessed 08 August 2019
  33. 33.
    Moisa AA, Kolesanova EF (2012) Synthetic peptide vaccines. In: Roy P (ed) An insight and control of infectious disease in global scenario. InTech, Rijeka CroatiaGoogle Scholar
  34. 34.
    Disis ML, Bernhard H, Shiota FM, Hand SL, Gralow JR, Huseby ES, Gillis S, Cheever MA (1996) Granulocyte-macrophage Colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88(1):202–210CrossRefGoogle Scholar
  35. 35.
    Liu F, Feuer R, Hassett DE, Whitton JL (2006) Peptide vaccination of mice immune to LCMV or vaccinia virus causes serious CD8+ T cell mediated, TNF-dependent immunopathology. J Clin Investig 116(2):465–475CrossRefGoogle Scholar
  36. 36.
    Roy P, Dey S, Nandy A, Basak SC, Das S (2019) Base distribution in dengue nuceotide sequences differs significantly from other mosquito-borne human-infecting Flavivirus members. Curr Comput Aided Drug Des 15:29–44CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2020

Authors and Affiliations

  • Ashesh Nandy
    • 1
  • Smarajit Manna
    • 1
    • 2
  • Subhash C. Basak
    • 3
  1. 1.Centre for Interdisciplinary Research and EducationKolkataIndia
  2. 2.Jagadis Bose National Science Talent SearchKolkataIndia
  3. 3.Department of Chemistry and BiochemistryUniversity of MinnesotaDuluthUSA

Personalised recommendations